Trisenox arsenic trioxide: Phase II; marketed to treat refractory acute promyelocytic leukemia (APL)

Preliminary data from a U.S. Phase II trial showed 1

Read the full 102 word article

How to gain access

Continue reading with a
two-week free trial.